GlassScriptPhysician profile
Mimi L Tran
NPI 1396497905
$6,382.91
in general payments reported to CMS, 2019-2025
31 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,123 · 2023: $2,098 · 2024: $2,137 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,235 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,235.38 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,271.71 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $762.90 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $697.12 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $568.43 | 2022-2025 | Evenity, Prolia, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $461.08 | 2022-2025 | |
| Insulet Corporation | $372.51 | 2022-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $328.80 | 2022-2025 | Isturisa, Signifor Lar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.86 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $213.20 | 2022-2025 | Imfinzi, Farxiga |
| Corcept Therapeutics | $211.18 | 2022-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $172.33 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $162.44 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $98.45 | 2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $90.75 | 2023-2025 | Tymlos |
| Eusa Pharma (US) LLC | $85.41 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $78.02 | 2025 | |
| Currax Pharmaceuticals LLC | $74.20 | 2023-2025 | Contrave, Nexletol, Nexlizet |
| Abbvie INC. | $72.04 | 2023-2024 | |
| Almatica Pharma LLC | $68.02 | 2024-2025 | Teriparatide, Loreev Xr |
| Amneal Pharmaceuticals LLC | $55.24 | 2022-2025 | Unithroid |
| Medtronic, INC. | $46.22 | 2024-2025 | Minimed 780g |
| Amryt Pharma Holdings LTD | $42.29 | 2022-2023 | Myalept |
| Ascensia Diabetes Care US INC. | $40.16 | 2023 | |
| Merck Sharp & Dohme LLC | $30.66 | 2022 | |
| Averitas Pharma INC. | $28.55 | 2023 | Qutenza |
| Ipsen Biopharmaceuticals, INC | $24.29 | 2022 | |
| Recor Medical INC | $21.56 | 2025 | Paradise Ultrasound Renal Denervation System |
| Nevro Corp. | $16.76 | 2023 | Senza |
| Kyowa Kirin, INC. | $16.64 | 2023 | |
| Embecta Corp. | $15.07 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ibsa Pharma INC. | $14.02 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.